Pulmonary sarcoidosis with or without extrapulmonary manifestations research hub

A Long-term Multicenter Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra pulmonary Involvement

This study is looking at a new medicine, XTMAB-16, for people with sarcoidosis that affects their lungs, and sometimes other parts of their body. It wants to see if the medicine is safe over a long time and if it continues to work well.